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Idiopathic Intracranial Hypertension (IIH)
• Disorder characterized by elevated intracranial pressure (ICP)
• Named meningitis serosa by Quincke in 1893
• Described by Walter Dandy in seminal paper in 1937
• AKA: pseudotumor cerebri or benign intracranial hypertension
• Incidence: 0.5–2/100,000 in the general population and a greater
Incidence: 12–20 /100,000 among women of child-bearing
• 10 times more common in women
• Obesity increases risk x 20

Idiopathic Intracranial Hypertension (IIH)
Clinical presentation
• Obese woman of childbearing age who complains of headaches and is
found to have papilledema on funduscopic examination
• Headaches
• Pulse synchronous tinnitus
• Visual symptoms: transient visual obscurations, horizontal diplopia,
sustained visual loss
• Absence of localized findings in neurological examination (except VIth nerve
palsy)
• Normal CT/MRI without hydrocephalus or mass
• CSF opening pressure >25 cm H2O with normal CSF
• No other causes of elevated ICP

Idiopathic Intracranial Hypertension (IIH)
• Elevated ICP is corroborated by papilledema in 95% of cases
• Papilledema = elevation of the optic disc, blurring of the optic disc
margin, and obscuration of major vessels; Frizen grading 1->5
• => Visual field loss and transient visual obscurations, usually slowly
over months/years
• Papilledema results in permanent vision field loss (25%) and decline
in visual acuity if treatment is delayed
• 3% of patients present with fulminant vision loss
• Pulsatile tinnitus reported in 52%–60% of patients

Idiopathic Intracranial Hypertension (IIH)
Pathophysiology
• Pathophysiology of the disorder remains highly speculative
• IIH literature has focused on the tenets of increased CSF production,
decreased CSF absorption, increased venous sinus pressure, and
factors such as obesity that may influence these mechanisms
• Venous sinus stenosis (narrowing) in identified in up to >90% of IIH

Idiopathic Intracranial Hypertension (IIH)
Pathophysiology

Idiopathic Intracranial Hypertension (IIH)
Management of IIH:

1. Medical Therapy

• The first-line treatment for IIH is weight loss and medical management.
• Carbonic anhydrase inhibitor Acetazolamide (Diamox) modest benefit compared to
placebo RCT (class IB evidence).
• The IIH Treatment Trial showed statistically significant effects of acetazolamide:
1. improved visual field function/decrease in papilledema grade
2. improved quality-of-life measures
3. decreased CSF pressure when compared to placebo
• Acetazolamide group adverse events:
electrolyte disturbances, nephrolithiasis, paresthesias, dysgeusia, nausea/vomiting,
diarrhea and fatigue

Idiopathic Intracranial Hypertension (IIH)
Management of IIH:
2. Optic nerve sheath fenestration
• Indication: medically refractory IIH (10%) who present with severe
vision loss and minimal headache symptoms
• Slit in the edematous optic nerve sheath
• Associated with demonstrable postoperative improvement in visual
acuity and visual fields
•
•
•
•

59% - improved visual acuity, 95% - improvement or stable visual acuity
visual fields improved in 68%
Headaches improved in 44%
Papilledema improved or resolved in 80%

Idiopathic Intracranial Hypertension (IIH)
Management of IIH:

2. Optic nerve sheath fenestration

Idiopathic Intracranial Hypertension (IIH)
Management of IIH:
2. Optic nerve sheath fenestration
• Major complications: 1.5% orbital or retrobulbar hematomas, orbital
cellulitis, traumatic optic neuropathy and strabismus.
• Minor complications: 16.4% diplopia, pupillary dysfunction, anisocoria
and late failure
• Overall, complication rate was 18%, with 15% of patients requiring
additional procedures.
• By 6 - 12 months, probability of failure was 16%, which doubled at 3-5
years

Idiopathic Intracranial Hypertension (IIH)
Management of IIH:
3. CSF Flow Diversion
• Serial lumbar punctures can rapidly relieve IH and decrease ICP
• Used as temporizing measure until more definitive procedure
• Placement of ventriculo-peritoneal (VPS) or lumboperitoneal shunt (LPS)
• 86% of patients who presented with headache experienced improvement
in their headache with shunt placement
• Papilledema improved in 70% of patients.
• Complication & failure rate was high, with 43% of patients requiring
additional procedures, such as shunt revisions

Idiopathic Intracranial Hypertension (IIH)
???
VENOUS SINUS STENOSIS (VSS)  IDIOPATHIC INTRACRANIAL HYPERTENSION
? CAUSE or CONSEQUENCE ?

• Rohr et al. showed reversal of VSS following CSF diversion procedures in 3 pts
• Bono et al. showed the opposite in 9 pts: VSS persisted after medical therapy
for IIH
• Intrinsic vs. extrinsic VSS
• Rarely intrinsic: fixed anatomic variations like septal band, swollen arachnoid
granulation, chronic thrombosis, or trabecula in venous sinus +/- 2nd hit like

Idiopathic Intracranial Hypertension (IIH)
???
VENOUS SINUS STENOSIS (VSS)  IDIOPATHIC INTRACRANIAL HYPERTENSION
• Positive feedback loop theory

Idiopathic Intracranial Hypertension (IIH)
Management of IIH:
4. Venous Sinus Stenting
Indication: medically refractory IIH (10%) with VSS on imaging (MRV) (90%),
can be also done in fulminant vision loss
• Stenting of one (both) stenotic transverse/sigmoid sinus junction
• Venous manometry across the stenosis – venous pressure gradient
average 20 cm H2O, (cutoff for stent >10 cm H2O)
• Antiplatelet treatment: dual antiplatelet 6-12 weeks (ASA and Plavix) then
ASA 12 months

Idiopathic Intracranial Hypertension (IIH)

Venous Sinus Stenting in IIH

40 yo F, HA, Papilledema, not tolerating Diamox, BMI 54, CSF opening pressure 55

Idiopathic Intracranial Hypertension (IIH)

Pressure at torcular 50 cm H2O
Pressure in jugular bulb: 20 cm H2O
Pressure gradient: 30 cm H2O

Pressure at torcular 27 cm H2O
Pressure in jugular bulb: 20 cm H2O
Pressure gradient: 7 cm H2O

33 yo F, BMI 35, HA and grade 5 papilledema

Pressure at torcular 44 cm H2O
Pressure in jugular bulb: 19 cm H2O
Pressure gradient: 25 cm H2O

Intrinsic residual stenosis despite 8 mm x 40 mm self-expanding stent

Pressure at torcular 24 cm H2O
Pressure in jugular bulb: 19 cm H2O
Pressure gradient: 5 cm H2O

Venous Sinus Stenting for IIH
Adverse effects: (serious <3%)
• Patients are on DAP for 6 - 12 weeks, then ASA for 1 year
• Ipsilateral headache for a few days, can relate to dural stretching
• In-stent thrombosis and adjacent recurrent stenosis
• Dural AVF formation has been described in 2 cases
• SDH, SAH, ICH, <2 % - periprocedural complication
• Transient hearing loss

Venous Sinus Stenting for IIH
Overall results from literature:
• Headache gone/improved in 80%
• Visual symptoms and papilledema improvement 85% at 4 weeks
• Pulsatile tinnitus improved 85%
Overall permanent morbidity/mortality <3%

37 yo M with headache, tinnitus, blurry vision, intermittent clear nasal fluid discharge
Headache worsened after CSF leak repair

Venous Sinus Stenting

LP opening pressure 38 cm H2O

Frisen grade 2 Papilledema

Pressure at torcular 48 cm H2O
Pressure in jugular bulb: 15 cm H2O
Pressure gradient: 32 cm H2O

Post 8 x 60 cm stent *
Pressure at torcular 27 cm H2O
Pressure in jugular bulb: 18 cm H2O
Pressure gradient: 9 cm H2O

*

Complete resolution of his headaches and tinnitus at 4 weeks,

Cerebral Venous Sinus Thrombosis (CVST)
and Venous Thrombectomy
• Uncommon cause of cerebral infarction - 0.5–1% of all strokes
• Incidence of adult CVST is 1.32 /100,000 person-years
• Initial treatment is systemic anticoagulation
• Endovascular intervention is an alternative option for patients
• Indication:
• Neurological deterioration despite anticoagulation
• Development of new or worsening intracerebral hemorrhage on
anticoagulation
• Contra-indication to systemic anticoagulation

Cerebral Venous Sinus Thrombosis
Virchow triad:

• Stasis
• changes in the vessel wall
• changes in the composition of the blood

Related to:
• Neoplasms
• infection
• Puerperium, pregnancy
• Systemic diseases
• Dehydration
• oral contraceptives (OCPs)
• Coagulopathies (Antithrombin III,
Protein C, and Protein S
Deficiency, APLA, Fact V Leiden)
• 30% of cases idiopathic

Clinical Findings:
I. Signs of increased ICP because of
impaired venous drainage
II. Focal brain injury from venous
ischemia/infarction or hemorrhage
Can result in:
• Cerebral edema
• Elevated intracranial pressure
• Hydrocephalus
• Hemorrhage
• Infarction
• Death

Cerebral Venous Sinus Thrombosis
Location:
• Superior sagittal sinus
• Transverse/sigmoid/jugular
• Cavernous sinus
• Isolated cortical vein/vein of
Labbe
• Deep venous system
• Multiple sinuses +/- Deep veins

Presentation:
Headache +
• Hemiparesis, aphasia
• Seizures, psychosis, hemianopia
• Diplopia
• Focal deficit
• Change in mental status

Cerebral Venous Sinus Thrombosis
Imaging:
• CT without contrast
• CT Venogram
• MRI
• MR Venogram:
• Time of Flight
• Phase contrast
• With contrast

• Digital Subtraction Angiography

Presentation:
• Hyperdensity of a cortical vein or
dural sinus
• Signs of Ischemia, hemorrhagic
infarction, ICH
• Non opacification of sinuses/veins
• Signs of venous
hypertension/collateral flow

Cerebral Venous Sinus Thrombosis
Imaging Pitfalls in Diagnosis:
• Positive findings of intraluminal
thrombus are key for high
confidence
• Often, non filling of a venous
sinus or cortical vein
• Thrombus signal variability and
imaging artifacts

• Anatomic variants of normal
venous anatomy may mimic
sinus thrombosis, including sinus
atresia/hypoplasia, asymmetrical
sinus drainage, and normal sinus
filling defects related to
prominent arachnoid
granulations or intrasinus septa
• ! Contrast enhanced MRV !

Cerebral Venous Sinus Thrombosis
Acute Management and Treatment of CVST
• Admission to stroke unit or Neuro ICU
• Anticoagulation therapy (3x RCT, IV Heparin, sq LMWH, sq Heparin)
• Disability free survival about 80%
• ICH <6%

• Clinical/neurologic deterioration: 9% to 13%
• Endovascular treatment: catheter directed thrombolysis and
mechanical thrombectomy

Venous Thrombectomy
Endovascular techniques
• Direct catheter thrombolysis
• Balloon-assisted thrombectomy
• Rheolytic catheter thrombectomy (AngioJet)
• Aspiration thrombectomy
• Stent retriever thrombectomy

36 yo F, family hx of hyperhomocysteinemia - presenting with severe HA and new onset seizures

Venous Thrombectomy

36 yo F, family hx of hyperhomocysteinemia - HA and seizures, started on iv Heparin drip, left hemiparesis, gaze deviation

36 yo F
Lethargy,
anisocoria,
rt pupillary
dilation
Emergent
decompressive
craniectomy

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

Follow-up CTV at 3 weeks

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

Follow-up at 6m, mRS 2, ambulatory, residual left arm + leg weakness

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

24 yo F, on OCP, hx of ulcerative colitis, recent diarrhea - presenting with severe HA and Rt hemiplegia, NIHSS 9

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

24 yo F, on OCP, hx of ulcerative colitis, recent diarrhea - presenting with severe HA and Rt hemiplegia, NIHSS 9

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

Albert L. Rhoton, Jr., M.D.

Albert L. Rhoton, Jr., M.D.

Albert L. Rhoton, Jr., M.D.

3 months follow-up MRI/MRV, mild residual rt hand weakness, mRS 1

Venous Thrombectomy

Albert L. Rhoton, Jr., M.D.

3 months follow-up MRI/MRV, mild residual rt hand weakness, mRS 1

Venous Thrombectomy
• Endovascular therapy can be considered if patients deteriorate
despite medical therapy or CI to systemic anticoagulation
• Catheter directed thrombolysis is effective but ICH rate over 15%
• Mechanical thrombectomy with systemic anticoagulation is more
effective in large clot burden, longstanding or hard clots
• Despite worse presentation, 70-80 % patients achieve functional
independence.
Albert L. Rhoton, Jr., M.D.

